Navigation Links
Two-Drug Combo Fights Brain Tumors
Date:10/19/2007

Avastin, irinotecan may hit the cancer at different points, researchers say

FRIDAY, Oct. 19 (HealthDay News) -- A combination of the drug bevacizumab (brand name Avastin) and the standard chemotherapy agent irinotecan may benefit patients with a type of deadly brain tumor called glioblastoma multiforme (GBM), says a Duke University pilot study.

This treatment approach may extend the length of time GBM patients can survive without tumor growth and may improve overall survival, according to researchers at Duke's Preston Robert Tisch Brain Tumor Center.

The study included 35 patients whose GBMs returned after they'd had standard therapy, possibly including surgery, radiation and chemotherapy. After the patients received the combination bevacizumab/irinotecan therapy, almost half had no tumor progression after six months, and 80 percent were still alive six months after diagnosis.

The findings are published in the Oct. 20 issue of the Journal of Clinical Oncology.

"These results represent tremendous hope for these patient and their families," lead investigator Dr. James J. Vredenburgh, a neuro-oncologist, said in a prepared statement.

He noted that 75 percent of patients with recurrent GBM treated with standard therapy, such as chemotherapy alone, have tumor progression at six months, and fewer than 50 percent are alive after six months.

"We speculate that bevacizumab and irinotecan each attack a particular characteristic of the tumor independently, or they work together, with bevacizumab suppressing the growth of blood vessels which makes the tumor more susceptible to the chemotherapy," Vredenburgh said.

"Further studies will tease out the exact mechanism of the therapy's success, and we also hope to study the effectiveness of this treatment in patients with newly diagnosed GBM," he added.

More information

The U.S. National Cancer Institute has more about brain tumors.



-- Robert Preidt



SOURCE: Duke University, news release, Oct. 18, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New Two-Drug Regime To Tackle Malaria
2. Drug Combo Works Better for children with ADHD, Tics
3. Scanning Combo Helps Detect Lung Cancer
4. Relief From Asthma With New Combo Therapy
5. Calcium-Vitamin D Combo For Reduced Fracture Risk
6. Drug Combo Improves Performance Of Multiple Sclerosis Drug
7. Alcohol-illusion: Alcohol and Energy Drinks Combo, Maintains Sobriety?
8. HER-2 Positive Breast Cancer Patients May Benefit With a Combo Drug Strategy
9. The Combo Treatment Is Effective to Treat Type 1 Diabetes in Mice
10. Doomed Duo: Obesity and Type 2 Diabetes Combo, Can Nip Life in the Bud
11. Arimidex-Herceptin Combo Therapy For Breast Cancer-Clinical Trial Findings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Rancho Palos Verdes, CA (PRWEB) , ... February ... ... well-being, and emotional flow is Dr. Carol Francis' goals for each ... Federation Retreat Conference, Dr. Carol Francis will demonstrate five different brainwave tools which ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth ... most widely used electronic patient signatures solution in healthcare . , Since ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... clinical operations executives and focusing on all facets of clinical trial planning and ... management , patient engagement, and more. In addition, attendees stopping by Pharmica’s booth ...
(Date:2/17/2017)... Atlanta, GA (PRWEB) , ... February 17, 2017 , ... ... ways to reduce readmissions. Driven in large part by the Hospital Readmission Reduction Program ... has been a key focus area for hospitals across the nation. While many providers ...
(Date:2/17/2017)... ... 17, 2017 , ... Dillon Ruxton Insurance, a Florida-based agency ... in the greater Fort Lauderdale metropolitan region, is embarking on a cooperative food ... years, LifeNet 4 Families has provided a broad range of food provision services ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... 16, 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of innovative therapies ... that Vincent J. Angotti has been ... the company,s board of directors, effective Monday, March ... of experience leading executive and commercial teams at ...
(Date:2/16/2017)... , Feb. 16, 2017  Prescription pain medications ... department visit are necessary for long-term opioid use to ... Feb. 16 th edition of The New ... "Emergency physicians see more patients in acute pain than ... Parker , MD, FACEP, president of the American College ...
(Date:2/16/2017)... , Feb 16, 2017 Research and ... Cancer Diagnostics Market Analysis & Trends - Function, Application, Cancer Type, ... ... Generation Cancer Diagnostics Market is poised to grow at a CAGR ... million by 2025. Some of the prominent ...
Breaking Medicine Technology: